Treatments for SMA

There are currently two treatments for SMA approved in Europe. Both increase the production of SMN, a protein essential for the survival of motor neurons.

Spinraza™: This compound is marketed by the pharmaceutical company Biogen and was approved for the treatment of SMA in Europe in June 2017 by the European Commission

ZolgensmaZolgensma™: This compound is marketed by the pharmaceutical company Novartis (AveXis) and approved for the treatment of SMA in Europe in May 2020 by the European Commission

 

More information